Park Ha Biological Technology (BYAH) Current Deferred Revenue (2023 - 2026)

Park Ha Biological Technology has reported Current Deferred Revenue for 4 years, with the latest figure at $194968.0 in Q2 2026.

• On a quarterly basis, Current Deferred Revenue rose 64.84% year-over-year to $194968.0 in Q2 2026; TTM through Apr 2026 was $194968.0, a 64.84% increase from a year earlier, with the FY2025 full-year figure at $194753.0, down 40.25% from the prior year.
• Current Deferred Revenue was $194968.0 for Q2 2026 at Park Ha Biological Technology, roughly flat from $194753.0 in the prior quarter.
• The five-year high for Current Deferred Revenue was $325924.0 in Q4 2024, with the low at $118277.0 in Q2 2025.
• Average Current Deferred Revenue over 4 years is $216894.2, with a median of $194968.0 recorded in 2026.
• The sharpest annual moves came in 2025 and 2026: Current Deferred Revenue sank 40.25% in 2025, then soared 64.84% in 2026.
• Over 4 years, Current Deferred Revenue stood at $250549.0 in 2023, then surged by 30.08% to $325924.0 in 2024, then plunged by 40.25% to $194753.0 in 2025, then rose by 0.11% to $194968.0 in 2026.
• The last three Current Deferred Revenue figures came in at $194968.0 (Q2 2026), $194753.0 (Q4 2025), and $118277.0 (Q2 2025), per Business Quant data.